Caplin Point Laboratories Ltd.

NSE: CAPLIPOINT | BSE: 524742 | ISIN: INE475E01026 | Industry: Pharmaceuticals
| Falling Comet

1829.10
2.14%
ICICI Direct
Firm expansion plans in place- In the US, the company is optically transitioning to B2C model to focus on high margin products. The company is also looking for third party ANDAs (4 already acquired, 5 more to come) as well as outsourcing some in-house products to the CMOs for optimal plant utilisation. This, we believe is a part of larger strategy where the company wants to increase the offerings via front-end and at the same time focusing on margin expansion. The legacy LatAm growth was slower seemingly on account of some saturation in the existing markets and focus...
Number of FII/FPI investors decreased from 198 to 190 in Sep 2025 qtr
More from Caplin Point Laboratories Ltd.
Recommended